Evgen Pharma Share Discussion Threads

[supernumerary] 11/12/2017 11:01

Just goes to show there are no slam dunks in the biotech business. The researchers in this COPD trial sound utterly bewildered by the result, but all credit to them for publishing...

[rathean] 11/12/2017 09:36

RNS 3rd party research RNS stating Evgen phase two trials now fully funded with results expected later in 2018.

[tilly99] 10/12/2017 13:00

1pd?Really? Wow

[dave444] 09/12/2017 13:51

I would not be surprised if it hit 12p but a £1/share price would not surprise me by February

[tilly99] 09/12/2017 13:25

Dave444Price tgt?

[pdt] 09/12/2017 10:37

I see they now have two live recruiting sites in Belgium, one in Spain and four in the UK. With others listed in France, Spain and the UK which are not yet recruiting. Looks like they will hit their date of end of 2018 for metastatic breast cancer.

However, I would expect them to tie up a licence deal long before then. Possibly even before the H1 2018 interim read out.

There should be good newsflow in 2018 with other activities and third party investigations. I did see MS was not mentioned but Stroke (other than subarachnoid) and Brain cancer seem to be new?

[dave444] 08/12/2017 16:58

Clearly a placing would hav that impact smart ass!!

[papillon] 08/12/2017 16:49

dave444 5 Dec '17 - 08:12 - 89 of 95 0 0
Well just had a small top up as 15p seems to be as low as it goes

dave444 6 Dec '17 - 08:35 - 92 of 95 0 0
Should be a good run up to Xmas

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Obviously not!

[pdt] 08/12/2017 12:47

Rathean - agreed. That was the section I was going to cut and paste.

Excellent news on nearly 12 month disease free progression for one person and others over 24 week disease free progression. This is a hugely valuable market. $5 billion per annum I believe was mentioned in the Hardman report.

And an amazing scientific breakthrough potentially turning metastatic breast cancer from a death sentence to a manageable condition. As Stephen Franklin was quoted in The Times article recently. This will literally save/extend hundreds of thousands of lives.

And good news on resolving the funding which was hanging over the company.

Only disappointing news I saw was that the stroke trial has probably been delayed a few months. I think the phrase is now "around year end" to finish.

[rathean] 08/12/2017 11:08

From the results:We are particularly pleased with the progress of the STEM trial and the requirement to open the compassionate use programme for patients that have had their tumour growth arrested for the full duration of the 24-week trial and wish to receive SFX-01 post-trial on ethical grounds. We now have one STEM patient that has been on SFX-01 for nearly a year with demonstrable clinical benefit and others that have entered the compassionate use programme.Successful placing and strong progress with SFX-01. One to top up and tuck under your pillow.

[rathean] 07/12/2017 13:25

Reached my buy-in price, pleased it fell back and maybe more to go with general sentiment today but firm believer in the science and progress made so far.

[dave444] 06/12/2017 08:35

Should be a good run up to Xmas

[dave444] 06/12/2017 08:11

I must be a prophet or something- ok more like something

[dave444] 06/12/2017 08:05

More upward momentum

[dave444] 05/12/2017 08:12

Well just had a small top up as 15p seems to be as low as it goes

[qazwsxedc69] 28/11/2017 11:59

In for a nibble here at 16p. Strikes me as a buy and tuck away kind of share.

[pdt] 24/11/2017 10:17

I also agree Timbo, looks like the price is sinking back to where it started.

Seperately I see there has been a positive follow up on an earlier autism study. And Evgen have mentioned they may work with St Thomas's in 2018 on an Autism study.

"Sulforaphane from Broccoli Reduces Symptoms of Autism: A Follow-up Case Series from a Randomized Double-blind Study"



From the original study: "Of the 26 participants who were taking SF throughout the study, 17 (65%) improved significantly, most of whom returned to baseline levels 4 weeks after terminating the intervention. None of those on placebo had changed significantly."

[dave444] 24/11/2017 07:21

Timbo. I agree

[timbo003] 24/11/2017 00:37

There doesn't seem to be any material event behind the recent rise, so presumably the reason is just another Pump and Dump. However, if the share price ends up higher than where it started , it will have served a useful purpose.

I suspect the company will want to find a bit of cash from somewhere before they get the first readout from the two ongoing clinical studies and according to the last Hardman report they will be running on empty by March next year. If the cash is to come from an equity based fund raise (which seems likely), then the higher the price the better as far as I am concerned.

[recordz] 23/11/2017 16:14

It's still up 36.3%.

[bin bag aim shares] 23/11/2017 15:52

LOL

a few years.

what else can you see?

Dead people ????

Pump is over

now the dump, I am afraid

[letmepass] 23/11/2017 15:09

Nice free float at the moment.. Will buy on weakness.. Can see this in £ in a few years

[dr sexington] 23/11/2017 12:45

Even close high today, selling tomorrow would crash the share price

[dr sexington] 23/11/2017 12:44

Letmepass

Got killed here?

Look where it was trading yesterday morning !!